The Mosaic drug development platform is the first to deliver the scalability of in vivo data generation with single-cell precision; The data will form the world's largest atlas of how drugs interact with a patient's cells.
This approach combines the atlas with artificial intelligence models to capture the in vivo disease context early in discovery and to better represent patient diversity in drug response in current in vitro trials.
Backed by renowned investors and founded by pioneers at the intersection of life sciences and technology, including co-founder Kevan Shokat.
SAN FRANCISCO , Dec. 8, 2022 /PRNewswire/ -- Vevo Therapeutics, a biotechnology company whose Mosaic platform uses next-generation AI models to develop in vivo drugs and find better medicines for more patients, today launched a milestone project. subscriptions and $12 attraction. millionth round of funding. Wing Venture Capital and General Catalyst co-led Mubadala Capital, AIX Ventures and Camford Capital.
The company's Mosaic platform is the first to provide the scalability to generate in vivo data with single-cell precision, as well as capture patient drug responses. In a single in vivo experiment, Mosaic can measure how a drug affects cells from tens or hundreds of patients, generating millions of data points about changes in gene expression caused by drugs. With the seed funding, Vevo will conduct thousands of Mosaic experiments to create what is now considered impossible: an in vivo atlas of how chemistry destroys biology. Vevo AI models will be trained on this atlas to detect new targets and agents that other technologies cannot detect.
The Vevo platform is based on technology developed by its two co-founders, Hani Gudarzi, Ph.D., Associate Professor at the University of California, San Francisco (UCSF), and Johnny Yu , Ph.D., Chief Scientist. Vevo Therapy The company holds an exclusive technology license from UCSF Innovation Ventures, which handles licensing and business development on behalf of the university.
"We created Vevo to solve a big problem in drug discovery: drugs found in in vitro models don't work for patients," says Dr. Nima Alidoust, CEO and founder of Vevo. "Drug discovery is just as important as the data that fuels it, and this data is currently generated out of the context of how disease occurs in living organisms, and also ignores the diverse mosaic of genetic backgrounds among patients that respond differently to each drug. In By launching and driving drug discovery with high-resolution in vivo data, we are changing the landscape of traditional discovery methods."
Although in vivo models are the gold standard for disease modeling, they are neither scalable nor accurate for early diagnosis. Limited to in vitro testing, early discovery efforts often overlook valuable targets that could be detected in vivo . Although new targets and drugs have been discovered in vitro , many of them will not be useful when tested in vivo or in humans.
"Most first-generation small-molecule drugs will work with limited efficacy in a small number of patients, and improvements will be slow during second- and third-generation advances," says co-founder Kevan Shokat , Ph.DD. Courtesy of Vevo Therapeutics. and professor at UCSF. "The ability to test drugs in many patients and generate single-cell data using in vivo models early in drug development will ultimately allow us to skip generations of incremental improvements to get better drugs to patients faster."
"The advent of AI in drug development has done little to reduce the number of drugs that fail clinical trials, as many use AI to plug cracks in an imperfect system," says Gaurav Garg , partner and member of Wing Venture Capital. Vevo's board of directors. "Vevo has made it possible to train artificial intelligence on known data from the ground up, creating a new way of drug discovery."
"I believe the best drug discovery innovations of our time will be those that can be used to reinvent the discovery process, complementing traditional drug discovery efforts," said Deep Nishar, CEO of General Catalyst. “That's what we think is most extraordinary about Vevo's technology and ambition. Not surprisingly, they discovered new cancer targets that were not detected by conventional methods, despite years of research and investment in the field before everything was established. IT pipeline and artificial intelligence".
"The Vevo platform removes the key limitations of drug discovery, namely the poor predictive power of preclinical models, the lack of generalizability to patients, and the limited understanding of how drugs work," says Ayman Al-Abdallah , partner at Mubadala Capital. "Vevo's technology, combined with the tenacity and professionalism of its team, has the potential to change the way drug discovery is done and help patients with unmet needs."
About Vevo Therapeutics
Vevo Therapeutics is a biotech company that uses its in vivo drug development platform and next-generation AI models to find the best drugs for more patients. The company's Mosaic platform is the first to scale in vivo data generation with single-cell precision to capture in vivo disease context early in drug discovery and to better represent patient diversity in drug response in today's in vitro testing. Vevo is using Mosaic to build the world's largest in vivo atlas of how drugs interact with patients' cells and train AI models on their data to find new targets and drugs that other technologies can't find.
Headquartered in San Francisco, California, Vevo was founded by a group of inventors and thinkers who discovered drugs for "inappropriate" uses and invented new methods in genomics, computational biology and chemistry. Vevo is backed by leading investors at the intersection of life sciences and technology, including General Catalyst, Wing Venture Capital, Mubadala Capital, AIX Ventures and Camford Capital. Learn more at www.vevo.ai and follow us on LinkedIn and Twitter.
Vevo Therapeutics Media Relations
Peg Rusconi , Verge Scientific: prusconi@vergescientific.com
See source content for media download: https://www.prnewswire.com/news-releases/vevo-therapy-launches-with-oversubscribed-12m-seed-financing-to-discover-better-drugs-using- higher-resolution - in-vivo-generated-data-at-scale-301697743.html
SOURCE Vevo Therapeutics
.png "admin")
Post a Comment
Post a Comment